<?xml version='1.0' encoding='utf-8'?>
<document id="22022867"><sentence text="Investigation of the metabolism of rufinamide and its interaction with valproate."><entity charOffset="35-45" id="DDI-PubMed.22022867.s1.e0" text="rufinamide" /><entity charOffset="71-80" id="DDI-PubMed.22022867.s1.e1" text="valproate" /><pair ddi="false" e1="DDI-PubMed.22022867.s1.e0" e2="DDI-PubMed.22022867.s1.e0" /><pair ddi="false" e1="DDI-PubMed.22022867.s1.e0" e2="DDI-PubMed.22022867.s1.e1" /></sentence><sentence text="Rufinamide was evaluated in vitro to determine which enzyme(s) are responsible for rufinamide hydrolysis and whether valproate, one of its metabolites (valproyl-CoA), and/or the rufinamide hydrolysis product (CGP 47292) could inhibit hydrolysis"><entity charOffset="0-10" id="DDI-PubMed.22022867.s2.e0" text="Rufinamide" /><entity charOffset="83-93" id="DDI-PubMed.22022867.s2.e1" text="rufinamide" /><entity charOffset="117-126" id="DDI-PubMed.22022867.s2.e2" text="valproate" /><entity charOffset="152-164" id="DDI-PubMed.22022867.s2.e3" text="valproyl-CoA" /><entity charOffset="178-188" id="DDI-PubMed.22022867.s2.e4" text="rufinamide" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e0" e2="DDI-PubMed.22022867.s2.e0" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e0" e2="DDI-PubMed.22022867.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e0" e2="DDI-PubMed.22022867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e0" e2="DDI-PubMed.22022867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e0" e2="DDI-PubMed.22022867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e1" e2="DDI-PubMed.22022867.s2.e1" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e1" e2="DDI-PubMed.22022867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e1" e2="DDI-PubMed.22022867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e1" e2="DDI-PubMed.22022867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e2" e2="DDI-PubMed.22022867.s2.e2" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e2" e2="DDI-PubMed.22022867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e2" e2="DDI-PubMed.22022867.s2.e4" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e3" e2="DDI-PubMed.22022867.s2.e3" /><pair ddi="false" e1="DDI-PubMed.22022867.s2.e3" e2="DDI-PubMed.22022867.s2.e4" /></sentence><sentence text=" Rufinamide hydrolysis was mediated primarily by human carboxylesterase (hCE) 1 and was nonsaturable up to 500 Î¼M"><entity charOffset="1-11" id="DDI-PubMed.22022867.s3.e0" text="Rufinamide" /></sentence><sentence text=" Two-thirds of rufinamide hydrolysis was estimated to occur in human microsomes and one-third in cytosol"><entity charOffset="15-25" id="DDI-PubMed.22022867.s4.e0" text="rufinamide" /></sentence><sentence text=" Valproate was a selective inhibitor for hCE1 compared to hCE2 and inhibition had a greater impact on rufinamide hydrolysis in microsomes than in cytosol"><entity charOffset="1-10" id="DDI-PubMed.22022867.s5.e0" text="Valproate" /><entity charOffset="102-112" id="DDI-PubMed.22022867.s5.e1" text="rufinamide" /><pair ddi="false" e1="DDI-PubMed.22022867.s5.e0" e2="DDI-PubMed.22022867.s5.e0" /><pair ddi="false" e1="DDI-PubMed.22022867.s5.e0" e2="DDI-PubMed.22022867.s5.e1" /></sentence><sentence text=" Valproyl-CoA caused similar inhibition of rufinamide hydrolysis in both microsomes and cytosol"><entity charOffset="43-53" id="DDI-PubMed.22022867.s6.e0" text="rufinamide" /></sentence><sentence text=" Carboxylesterases were not significantly inhibited by CGP 47292" /><sentence text=" Inhibition of in vitro rufinamide hydrolysis by valproate could offer an explanation for the observed in vivo drug-drug interaction between the two antiepileptic drugs"><entity charOffset="49-58" id="DDI-PubMed.22022867.s8.e0" text="valproate" /></sentence><sentence text="" /></document>